A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial) - Quiz - MDSpire

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

  • By

  • Kedar Kirtane

  • Jiaxin Niu

  • George Blumenschein

  • Erminia Massarelli

  • Glenn J. Hanna

  • Sylvia Lee

  • Michael R. Bishop

  • Gottfried E. Konecny

  • Daqin Mao

  • Yan Zheng

  • Katherine Rodriguez

  • Jenny J. Kim

  • Chad Williams

  • Colleen Schweitzer

  • Sabina Adhikary

  • A. Scott Jung

  • Christopher A. Klebanoff

  • May 21, 2026

  • 0 min

Share

Original Source(s)

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

  • by Kedar Kirtane, Jiaxin Niu, George Blumenschein, Erminia Massarelli, Glenn J. Hanna, Sylvia Lee, Michael R. Bishop, Gottfried E. Konecny, Daqin Mao, Yan Zheng, Katherine Rodriguez, Jenny J. Kim, Chad Williams, Colleen Schweitzer, Sabina Adhikary, A. Scott Jung, Christopher A. Klebanoff

  • May 21, 2026

Related Content

Potential targets for boron transport in boron neutron capture therapy

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer